Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
Subtype terms (4)
More specific conditions that are subtypes of Brain Ischemia in the MeSH hierarchy.
- Brain Infarction
14 drugs (8 approved, 6 experimental)
- Hypoxia-Ischemia, Brain
44 drugs (28 approved, 16 experimental)
- Ischemic Attack, Transient
46 drugs (37 approved, 9 experimental)
- Vertebrobasilar Insufficiency
3 drugs approved
Drugs by status
Phase 4 trials (13)
Phase 3 trials (11)
Phase 2 trials (16)
Phase 1 trials (5)
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (28)
- Centocor
- Eli Lilly
- Hamad Medical Corporation
- Neurobiological Technologies
- NoNO Inc.
- Pharmazz, Inc.
- National Cerebral and Cardiovascular Center
- University of Pennsylvania
- Pakistan Army
- Semmelweis University
- University of Heidelberg
- University of Sydney
- University of Toronto
- University of Bordeaux
- Assiut University
- Dalhousie University
- Kwong Wah Hospital
- Netherlands Organisation for Scientific Research
- University of British Columbia
- University of Calgary
- Mitsubishi Tanabe
- University of Paris
- National Health and Medical Research Council, Australia
- Trillium Health Partners
- Brain Canada
- Djavad Mowafaghian Centre for Brain Health
- Canadian Stroke Network
- Kyowa Hakko Kogyo
Organization Involved with Phase 2 Indications (44)
- Celgene
- Pfizer
- Prolong Pharmaceuticals
- D-Pharm Ltd.
- Ain Shams University
- Case Western Reserve University
- University of London
- Duke University
- University of Washington
- Guangxi Medical University
- Guangzhou Medical University
- Johns Hopkins University
- Kaiser Permanente
- Medical University Innsbruck
- Memorial University of Newfoundland
- New York Medical College
- Oregon Health and Science University
- Russian Academy of Medical Sciences
- Stanford University
- Tanta University
- University of Florence
- University of Maryland
- University of New Mexico
- University of Pisa
- University of Alberta
- University of Arkansas
- University of Bristol
- University of Waterloo
- Fudan University
- Zhengzhou University
- +14 more
Organization Involved with Phase 1 Indications (26)
- Translational Sciences, Inc.
- National Institute of Neurological Disorders and Stroke (NINDS)
- Hebei University
- China Spinal Cord Injury Network
- Harvard University
- Hospital Universitario Hernando Moncaleano Perdomo
- KK Women's and Children's Hospital
- Nagoya University
- Singapore General Hospital
- University of Florida
- Chinese University of Hong Kong
- St. Louis University
- Medical University of South Carolina
- City University of Hong Kong
- National University of Singapore
- The University of Hong Kong
- Universidad Surcolombiana
- Hospital Hernando Moncaleano Perdomo
- University of North Carolina at Chapel Hill
- National Institute for Health Research, United Kingdom
- Dr. Jeffrey Thomas Stroke Shield Foundation
- StemCyte, Inc.
- Government of Singapore
- Mononuclear Therapeutics Ltd.
- Universidad Carlos III Madrid
- Life Science Institute, Inc.
Organization Involved with Other Experimental Indications (17)
- United States Navy
- Centre Hospitalier le Mans
- City Clinical Hospital No. 67, Moscow, Russia
- Gachon University
- Life Recovery Systems
- Tulane University
- University of Lausanne
- AUSL della Romagna-RAVENNA
- University of Ferrara
- University of Montpellier
- Al Azhar University
- Government of China
- Universitaetsklinikum Schleswig-Holstein
- Bethune International Peace Hospital
- Shangluo Central Hospital
- University of South China
- People's Liberation Army of China